SCoPE - BCcampus Learning + Teaching

Immunotherapy has recently emerged as a viable approach to cancer treatment. Although the recent clinical trials validate the overall approach of immunotherapy and hint at a greater potential, most patients still need more effective treatments, underscoring the heterogeneity of human antitumor immune responses. Unfortunately, our understanding of human cancer immunology is currently limited. However, mouse tumor models remain an almost obligatory stepping stone to undertaking studies in patients with cancer.

Cell line-Derived Xenograft (CDX) model is a well-established and commonly used mouse tumor model type for the research and development of anti-tumor drugs and immunotherapy. More recently, human tumors implanted directly into immunodeficient mice have become increasingly popular as evidence accrues that they more accurately recapitulate features of patient tumors. However, CDX model still possesses pervasive application at the early stage of in vivo study, due to its user-friendly techniques as well as excellent repeatability.

With years of operational experience and technology platform of CDX models, Creative Bioarray focuses on anti-tumor drug research and development services to help customers assess the efficacy of compounds and study the associated pathological mechanisms.